Lineage Cell Therapeutics (LCTX) Q2 2026 earnings summary

Executive summary

• Advanced cell therapy pipeline leveraging the AlloSCOPE platform, with OpRegen as the lead asset in Phase 2a for geographic atrophy under Roche/Genentech partnership, and rapid progress in COR1, ILT1, and ReSonance/ANP1 programs.

• OpRegen program continues with positive 3-year Phase 1/2a data, ongoing surgical optimization, expanded clinical trial sites (17), and EMA IRIS registration.

• COR1 (corneal endothelial cell therapy) advanced to in-vivo animal testing, targeting Fuchs Endothelial Corneal Dystrophy and Bullous Keratopathy, with initial preclinical data expected in 2026.

• OPC1 program shifted focus to chronic spinal cord injury patients, with ongoing DOSED study and positive safety profile.

• ReSonance/ANP1 (auditory neuronal cell therapy) advancing in preclinical development with Demant partnership funding and successful GMP run.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $50.8 million as of June 30, 2026, expected to fund operations into Q3 2028.

• Q2 2026 revenue was $1.1 million, down from $2.8 million year-over-year, mainly due to lower collaboration and royalty revenues.

• Operating expenses decreased to $10 million from $22.5 million year-over-year, reflecting the absence of a prior year $14.8 million impairment charge.

• Net income for Q2 2026 was $1.5 million, or $0.01 per basic share, compared to a net loss of $30.5 million in Q2 2025, driven by non-cash gain from warrant liability remeasurement.

• R&D expenses increased to $4.8 million and G&A expenses to $5.2 million in Q2 2026.

Outlook and guidance

• Cash runway projected to support operations into Q3 2028.

• Anticipates further updates on diabetes (ILT1) and COR1 programs before year-end, with initial COR1 preclinical data expected in 2026.

• Ongoing enrollment in DOSED study for OPC1, with focus on chronic SCI patients and potential protocol adjustments.

• Continued expectation for OpRegen to advance into a multi-center controlled trial.

• Management anticipates continued operating losses and the need for additional capital to support future growth.